Piper Calls Valeant Management ‘Overly Rosy,’ Cuts Pr
Management of Valeant Pharmaceuticals (VRX) is taking an “overly rosy” long-term view of the business, Piper Jaffray analyst David Amsellem tells investors in a research note following the company’s Q4 results. The analyst cuts his price target for the shares to $10 from $12 and reiterates an Underweight rating on the name. Valeant closed…